399 related articles for article (PubMed ID: 30332496)
1. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
Katodritou E; Terpos E; Delimpasi S; Kotsopoulou M; Michalis E; Vadikolia C; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Vadikolia C; Michael M; Kalpadakis C; Gougopoulou T; Prokopiou C; Kaiafa G; Christoulas D; Gavriatopoulou M; Giannopoulou E; Labropoulou V; Verrou E; Kastritis E; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
Blood Cancer J; 2018 Mar; 8(3):31. PubMed ID: 29523783
[TBL] [Abstract][Full Text] [Related]
4. Primary Plasma Cell Leukemia: Identity Card 2016.
Musto P; Simeon V; Todoerti K; Neri A
Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
[TBL] [Abstract][Full Text] [Related]
6. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
7. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
8. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.
Pagano L; Valentini CG; De Stefano V; Venditti A; Visani G; Petrucci MT; Candoni A; Specchia G; Visco C; Pogliani EM; Ferrara F; Galieni P; Gozzetti A; Fianchi L; De Muro M; Leone G; Musto P; Pulsoni A;
Ann Oncol; 2011 Jul; 22(7):1628-1635. PubMed ID: 21252060
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
10. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
Wang H; Li JY; Sun C; Zhou X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
[TBL] [Abstract][Full Text] [Related]
11. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.
Nandakumar B; Kumar SK; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Siddiqui M; Go RS; Jevremovic D; Kyle RA; Gertz MA; Rajkumar SV; Gonsalves WI
Mayo Clin Proc; 2021 Mar; 96(3):677-687. PubMed ID: 33673918
[TBL] [Abstract][Full Text] [Related]
13. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
[No Abstract] [Full Text] [Related]
14. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
15. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma.
Iriuchishima H; Ozaki S; Konishi J; Matsumoto M; Murayama K; Nakamura F; Yamamoto G; Handa H; Saitoh T; Nagura E; Shimizu K; Nojima Y; Murakami H
Acta Haematol; 2016; 135(2):113-21. PubMed ID: 26505781
[TBL] [Abstract][Full Text] [Related]
16. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
18. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
D'Arena G; Valentini CG; Pietrantuono G; Guariglia R; Martorelli MC; Mansueto G; Villani O; Onofrillo D; Falcone A; Specchia G; Semenzato G; Di Renzo N; Mastrullo L; Venditti A; Ferrara F; Palumbo A; Pagano L; Musto P
Ann Oncol; 2012 Jun; 23(6):1499-502. PubMed ID: 22039089
[TBL] [Abstract][Full Text] [Related]
19. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]